Hippocampal atrophy in Alzheimer's disease

Hilkka Soininen (Corresponding Author), Yawu Liu, Daniel Rueckert, Jyrki Lötjönen

Research output: Contribution to journalArticleScientificpeer-review

Abstract

New research criteria for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) emphasize the use of imaging biomarkers in clinical diagnosis of these disorders. The volume loss of medial temporal lobe structures, especially hippocampal atrophy, is the best validated marker of AD. Manual tracing on MRI is the present gold standard for evaluating hippocampal volume; however, it is laborious and tracer-dependent. We categorized the most recent full- or semi-automated methods by the nature of the output of the method: size and shape of subcortical structures, cortical thickness, atrophy-rate and voxel- and region-based characteristics. The features of each method are introduced. The findings in structural MRI studies, especially in those studies utilizing the most recent methods, and the accuracies of those new methods in differentiating AD from healthy controls and stable MCI from progressive MCI are reviewed.
Original languageEnglish
Pages (from-to)197-209
JournalNeurodegenerative Disease Management
Volume2
Issue number2
DOIs
Publication statusPublished - 2012
MoE publication typeA1 Journal article-refereed

Fingerprint

Atrophy
Alzheimer Disease
Temporal Lobe
Biomarkers
Research
Cognitive Dysfunction

Keywords

  • Alzheimers disease
  • hippocampus
  • image quantification

Cite this

Soininen, H., Liu, Y., Rueckert, D., & Lötjönen, J. (2012). Hippocampal atrophy in Alzheimer's disease. Neurodegenerative Disease Management, 2(2), 197-209. https://doi.org/10.2217/nmt.12.13
Soininen, Hilkka ; Liu, Yawu ; Rueckert, Daniel ; Lötjönen, Jyrki. / Hippocampal atrophy in Alzheimer's disease. In: Neurodegenerative Disease Management. 2012 ; Vol. 2, No. 2. pp. 197-209.
@article{3a0580e6b86e4bb284c4eaad0f1f3eff,
title = "Hippocampal atrophy in Alzheimer's disease",
abstract = "New research criteria for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) emphasize the use of imaging biomarkers in clinical diagnosis of these disorders. The volume loss of medial temporal lobe structures, especially hippocampal atrophy, is the best validated marker of AD. Manual tracing on MRI is the present gold standard for evaluating hippocampal volume; however, it is laborious and tracer-dependent. We categorized the most recent full- or semi-automated methods by the nature of the output of the method: size and shape of subcortical structures, cortical thickness, atrophy-rate and voxel- and region-based characteristics. The features of each method are introduced. The findings in structural MRI studies, especially in those studies utilizing the most recent methods, and the accuracies of those new methods in differentiating AD from healthy controls and stable MCI from progressive MCI are reviewed.",
keywords = "Alzheimers disease, hippocampus, image quantification",
author = "Hilkka Soininen and Yawu Liu and Daniel Rueckert and Jyrki L{\"o}tj{\"o}nen",
note = "Project code: 18493",
year = "2012",
doi = "10.2217/nmt.12.13",
language = "English",
volume = "2",
pages = "197--209",
journal = "Neurodegenerative Disease Management",
issn = "1758-2024",
publisher = "Future Medicine Ltd.",
number = "2",

}

Soininen, H, Liu, Y, Rueckert, D & Lötjönen, J 2012, 'Hippocampal atrophy in Alzheimer's disease', Neurodegenerative Disease Management, vol. 2, no. 2, pp. 197-209. https://doi.org/10.2217/nmt.12.13

Hippocampal atrophy in Alzheimer's disease. / Soininen, Hilkka (Corresponding Author); Liu, Yawu; Rueckert, Daniel; Lötjönen, Jyrki.

In: Neurodegenerative Disease Management, Vol. 2, No. 2, 2012, p. 197-209.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Hippocampal atrophy in Alzheimer's disease

AU - Soininen, Hilkka

AU - Liu, Yawu

AU - Rueckert, Daniel

AU - Lötjönen, Jyrki

N1 - Project code: 18493

PY - 2012

Y1 - 2012

N2 - New research criteria for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) emphasize the use of imaging biomarkers in clinical diagnosis of these disorders. The volume loss of medial temporal lobe structures, especially hippocampal atrophy, is the best validated marker of AD. Manual tracing on MRI is the present gold standard for evaluating hippocampal volume; however, it is laborious and tracer-dependent. We categorized the most recent full- or semi-automated methods by the nature of the output of the method: size and shape of subcortical structures, cortical thickness, atrophy-rate and voxel- and region-based characteristics. The features of each method are introduced. The findings in structural MRI studies, especially in those studies utilizing the most recent methods, and the accuracies of those new methods in differentiating AD from healthy controls and stable MCI from progressive MCI are reviewed.

AB - New research criteria for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) emphasize the use of imaging biomarkers in clinical diagnosis of these disorders. The volume loss of medial temporal lobe structures, especially hippocampal atrophy, is the best validated marker of AD. Manual tracing on MRI is the present gold standard for evaluating hippocampal volume; however, it is laborious and tracer-dependent. We categorized the most recent full- or semi-automated methods by the nature of the output of the method: size and shape of subcortical structures, cortical thickness, atrophy-rate and voxel- and region-based characteristics. The features of each method are introduced. The findings in structural MRI studies, especially in those studies utilizing the most recent methods, and the accuracies of those new methods in differentiating AD from healthy controls and stable MCI from progressive MCI are reviewed.

KW - Alzheimers disease

KW - hippocampus

KW - image quantification

U2 - 10.2217/nmt.12.13

DO - 10.2217/nmt.12.13

M3 - Article

VL - 2

SP - 197

EP - 209

JO - Neurodegenerative Disease Management

JF - Neurodegenerative Disease Management

SN - 1758-2024

IS - 2

ER -